Given the success of anti-PD1, anti-PDL1, and anti-CTLA4 treatments in cancer patients, we compared the difference in the expression value of immune checkpoints (including PD-1, PD-L1, and CTLA-4), and the different subgroups categorized by the median of TIMSig. The gene discussed is CTLA4; the disease is cancer.